

TAE Life Sciences to Present Its Latest Advancements in Radiation Oncology at LSI Europe 2023

BARCELONA, Spain – September 12, 2023 – [TAE Life Sciences](#), a pioneer in accelerator-based Boron Neutron Capture Therapy (BNCT), announces its participation in the upcoming LSI Europe 2023 conference. The event, set to take place in Barcelona from September 18 to 22, will serve as a platform for TAE Life Sciences' CEO, Rob Hill, to deliver a keynote presentation on the future of radiation oncology and the company's revolutionary BNCT system and proprietary BNCT drugs.

Mr. Hill's live presentation promises to be a highlight of the LSI Europe '23 Emerging Medtech Summit. He will provide attendees with exclusive insights into the groundbreaking progress TAE Life Sciences has achieved in bringing BNCT to clinical trials globally. Moreover, Mr. Hill will delve into the unique features and benefits of their BNCT approach, offering a glimpse into the future of radiation oncology that holds great promise for patients with difficult-to-treat cancers worldwide.

“We’ve made incredible progress in bringing our BNCT solution to market on a global scale, and I’m thrilled to share these exciting updates with attendees at LSI Europe 2023,” said Rob Hill, CEO of TAE Life Sciences. “This conference presents a unique opportunity to connect with industry leaders, share our vision, and invite potential investors to participate in our series C funding round as we continue our mission to transform cancer treatment.”

LSI Europe '23 Emerging Medtech Summit is a premier event that brings together industry visionaries, thought leaders, and professionals worldwide. Hosted by [LSI](#) (Life Science Intelligence), a leading market intelligence company focused on the medtech industry headquartered in Orange County, California, USA, the summit is dedicated to advancing the medtech and health tech sectors.

TAE Life Sciences invites all conference attendees to join CEO Rob Hill's presentation on September 20th and learn more about the future of radiation oncology and the company's innovative BNCT technology.

Presentation Details

Who: Rob Hill, CEO at TAE Life Sciences

What: Presenting TAE Life Sciences' global progress in Boron Neutron Capture Therapy (BNCT), including the latest advancements and unique capabilities of Alphabeam

When: September 20th at 4:50 PM, Track 1

Where: LSI Europe, The Ritz-Carlton, Barcelona

For more information about TAE Life Sciences and its participation in LSI Europe 2023, please visit our website at www.taelifesciences.com.

About TAE Life Sciences

TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences' Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.

For media inquiries, please contact:

[New Era Communications](#)

Phone: (949) 346-1984

Email: TAE@newerapr.com